The successful completion of a Phase 3 study with positive results typically leads to increased investor confidence in the pharmaceutical sector, especially for the company behind the drug. Meeting all critical efficacy endpoints not only bodes well for the regulatory approval process but also positions the drug favorably in the market. This can lead to increased revenue projections for Teva, positively impacting its stock price in the short term.